Radioimmunotherapy in non-Hodgkin lymphoma: prediction and assessment of response
M Eskian, MH Khorasanizadeh… - Critical Reviews in …, 2016 - Elsevier
Non-Hodgkin lymphoma (NHL) is one of the most common malignancies and a major cause
of morbidity and mortality. Radioimmunotherapy (RIT) is a novel modality for treating NHL …
of morbidity and mortality. Radioimmunotherapy (RIT) is a novel modality for treating NHL …
单克隆抗体药物在恶性肿瘤靶向治疗中的应用
刘志芳 - 国际肿瘤学杂志, 2007 - cqvip.com
单克隆抗体药物在恶性肿瘤靶向治疗中的应用-[维普官方网站]-www.cqvip.com-维普网 我的维普
购物车 充值 客服 首页 | 期刊大全 | 文献分类 | 优先出版 | 论文检测 | 论文选题 | 在线分享 | 会议 …
购物车 充值 客服 首页 | 期刊大全 | 文献分类 | 优先出版 | 论文检测 | 论文选题 | 在线分享 | 会议 …
[PDF][PDF] Generación de un anticuerpo Bi-específico Anti-CD19 y CD16 mediador de citotoxicidad tumoral CD16 dependiente
OR Fajardo Ramírez - 2014 - eprints.uanl.mx
UNIVERSIDAD AUTÓNOMA DE NUEVO LEÓN Page 1 UNIVERSIDAD AUTÓNOMA DE
NUEVO LEÓN FACULTAD DE MEDICINA “GENERACIÓN DE UN ANTICUERPO BI-ESPECÍFICO …
NUEVO LEÓN FACULTAD DE MEDICINA “GENERACIÓN DE UN ANTICUERPO BI-ESPECÍFICO …
90Y-ibritumumab tiuxetan (Zevalin)
PL Zinzani - Hematology Meeting Reports (formerly Haematologica …, 2008 - pagepress.org
There is currently a range of different treatments available for the treatment of non-Hodgkin's
lymphoma (NHL). These include the more traditional therapies such as conventional …
lymphoma (NHL). These include the more traditional therapies such as conventional …